- Home
- WRN vs FDMT Comparison
WRN vs FDMT Comparison
Compare WRN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRN | FDMT |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.2M | 695.3M |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WRN | FDMT |
|---|---|---|
| Price | $2.36 | $14.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $4.58 | ★ $31.71 |
| AVG Volume (30 Days) | ★ 1.1M | 718.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $1.23 | $5.97 |
| 52 Week High | $4.26 | $15.03 |
Technical Indicators
Market Signals| Indicator | WRN | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 76.60 |
| Support Level | $2.25 | $8.43 |
| Resistance Level | $2.66 | N/A |
| Average True Range (ATR) | 0.08 | 0.82 |
| MACD | 0.02 | 0.44 |
| Stochastic Oscillator | 66.92 | 88.85 |
Price Performance
Historical ComparisonAbout WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).